Kolexia
Gay-Guerinet Julie Hématologie
Gay-Guerinet Julie
Hématologie
Centre Hospitalier de la Côte Basque
Bayonne, France
50 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Leucémie myéloïde Purpura Purpura thrombopénique Purpura thrombotique thrombocytopénique Macroglobulinémie de Waldenström

Collaborateurs

Voir plus
Banos Anne
Banos Anne
Centre Hospitalier de la Côte Basque, Bayonne, France
Capdupuy Claudie
Capdupuy Claudie
Centre Hospitalier de la Côte Basque, Bayonne, France
Chambon-Lopez Anne
Chambon-Lopez Anne
Centre Hospitalier de la Côte Basque, Bayonne, France
Araujo Carla
Araujo Carla
Cabinet libéral, Bayonne, France

Industries

Voir plus
Janssen
13 collaboration(s)
Dernière en 2023
AstraZeneca
6 collaboration(s)
Dernière en 2022
Abbvie
5 collaboration(s)
Dernière en 2023
Amgen
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
EVEREST: Assessment of the Quality of Life of Patients With Lymphomas Treated With Oral Therapy
Essai Clinique (CHU Toulouse)   18 septembre 2023
STAIR: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia
Essai Clinique (French Innovative Leukemia Organisation)   23 mai 2023
Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group
Annual Meeting Abstracts 2022   15 novembre 2022
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
Annual Meeting Abstracts 2022   15 novembre 2022
Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group
Blood   23 novembre 2021
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR
Blood   23 novembre 2021
Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group
Blood   05 novembre 2020
Impact et faisabilité de la nutrition entérale chez les patients autogreffés
Nutrition Clinique et Métabolisme   01 mars 2019
mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.
Haematologica   10 mai 2018